warning: Creating default object from empty value in /home/cpnhelp/www/www/modules/taxonomy/ on line 33.
Agents used to kill micro-organisms.

Cpn vs Lyme disease Rx?

Just chatting with a dear friend over in the Lyme boards.  She mentioned new guidelines for Lyme treatment, including increased dosing of doxyi/azith.  She takes 3x the doxy per day that I do, and is herxing like crazy...even suggesting that I try the same.  I know the Rx protocolsi for the two differ--but does anybody know why the cpni prot. has lower dosing? 

Sorry if it's a dumb question--my brain fog/headache are back today. 

Why the fluoroquinolone antibiotics are conspicuously absent from Stratton & Wheldon protocols

I am a 22-year old male CFIDSi patient who is part of a family "cluster" of CFSi associated with persistent c. pneumoniae infection, with both of my parents also affected.  I was initially treated with Zithromax 250mg/day and doxycycline 200mg/day for a year.  I experienced dramatic & sustained improvement in all symptoms, especially cognitive, within 10 weeks of starting treatment.  However, my clinician wanted me to stop treatment after a year due to the ill-defined 'dangers' of long-term antibiotic use, so I did, and the result was that I was clinically worse and PCRi positive for c. pneumoniae in the serum 10 weeks after stopping the antibiotics.  My clinician, who is not favorable towards the complicated Stratton protocol & who particularly disagreed with the use of metronidazolei, opted instead to prescribe me 6 weeks of Factive (gemifloxacin), a quinolone antibiotic that is highly active against c. pneumoniae.

Has anyone feel that the Abx routine is NOT helping


I think it is safe to say that anyone who reads all the

success stories about abxi treatment feels a sense of

hope.  But we also must talk about failures.


Have you or do you know of anyone that is deteriorating

from their illness in spite of the abx regimen.



(I begin my abx this weekend)

CPn, Rifampin and Resistence

Here< is a paper describing development of resistence in CPn in vitro studies using subinhibitory concentrations of the drug. CPn developed resistence after 12 cycles. It is not recommended to use single agents for CPn infection in chronic illness. The combination of macrolide and tetracycline effectively makes resistence impossible.

Negative Reactions to Treatment

Let's collect our various negative reactions to antibiotics. This was prompted by KitKat2 asking about my report of burning eyes and mucous membranes worsening from abxi use in my own story, something he had noticed as he started azithromycin. Maybe we can get some common themes.

Doxyi< - Don't get reactions at this point. When first took both, felt like a truck hit me: searing pain everywhere, burning eyes, floored with fatigue.

Azith-Ringing ears, sense of clogged pressure in ears.

Flagyli/Tinii<- Disoriented Nauseated (severe with Flagyl, mild with Tini) Aching all over. Aching knees, left wrist, left ankle and foot

Amoxicillini<- Burning eyes.Burning muscles, neck back, shoulders. Aching joints- sacroilleac, knees, hands, neck.

Kitkat2's "AX"-cellent Adventure!

Baseline Reference:

'83:  Severe bout of nystagmus,visual problems[depth perception], severe upper back muscle tension, stiff neck, extreme fatigue, pounding heartrate, dizziness, raw/red throat,nausea.  TX: 2 wks PenVK

(Neg strep/Neg EBi)

'83-'92:  Occasional sore throats, chronic sinusitis, nasal allergies.  Mild/moderate fatigue/dizziness.  Was labeled "Agoraphobic", but felt ill and dizzy even in the "relative" safety of my own home.

TX: EES, Amoxicillini, Augmentin, Keflex, numerous times/yr for sinus infectionsi.  Unsuccessful attempts at therapy groups to deal with "anxiety". 

'93:  Sudden episode of neck pain/stiffness, combined with mid-back tightness with resulting numbness/tingling in left hip/foot. This occurred with a lumbar disk problem, and lasted for months, making ambulation painful.

Cpn Treatment Information

The links below will take you to pages with specific information involved in the treatment of Cpni.

Diagnostic Testing For Cpn<
Information on serological testing and the problems of this in Cpn.
Combination Antibiotic Treatment Protocols for Cpn<
Links to pages on the current versions of Vanderbilt/Stratton and Wheldon Protocols for treating Cpn infectionsi in various diseasesi.
Experts Comments<

Commentary and interviews  with various experts in treating Cpn which help guide and inform about various facets of treatment.
Treatment Reactions<
Information on some of the kinds and sources of treatment reactions one can expect on combination antibiotic protocols in treating Cpn, including cytokinei reactions, endotoxini reactions, secondary porphyriai and other reactions. These are often lumped under the term "herx," an inaccurate term and not as useful as really understanding what's going on.


The Basics Page

Hello and Welcome!

This site is focused on treatment of chronic disease like Multiple Sclerosis (MSi) Chronic Fatigue Syndromei (CFSi) and Fibromyalgia (FMSi) an many other diseasesi with antibioticsi. Recent research indicates that Chlamydia Pneumoniae (CPni) plays a role in these diseases.

Here are the basics that make it easier for people new to the site to get going (if your brain isn't ready for even this much right now-- we've all been there-- read Cpn Simple< first):

Is this a sexually transmitted disease? No. this is chlamydia pneumoniae, a bacteria that can cause pneumonia. It may soon be called chlamydiophilia (meaning in the family of).

Is chlamydia pneumoniae (CPn) rare?

Pilot study to examine effect of antibiotic therapy on MRI outcomes in RRMS

Journal of Neurological Science 2005 Jul 15;234(1-2):87-91

"Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMSi"

The rights to this paper are owned by Elsevier. the whole citation can be purchased


Sriram S, Yao SY, Stratton C, Moses H, Narayana PA, Wolinsky JS.

Department of Pathology, Vanderbilt University Medical Center, Nashville, TN 37212, USA.

This trial examined the safety and possible MRI and clinical effects of anti-chlamydial antibiotic therapy in relapsing-remitting MS (RRMS). Newly diagnosed MS patients were selected to participate if they showed Chlamydia pneumoniae gene in their CSF and had one or more enhancing lesions on brain magnetic resonance imaging (MRI). After a 4-month run in phase of monthly MRI, patients were randomized to receive rifampin (300 mg twice daily) and azithromycin (500 mg every other day) for 6 months or placebo (PBO). Patients then had monthly MRI on therapy and two additional scans on months 12 and 14. Lumbar punctures were repeated between months 7 and 8 and within 2 weeks of termination of the study. Data on 4 patients on treatment and 4 on PBO were available for analysis. The primary outcome measure of showing a beneficial effect on enhancing lesions was not met. However, there was a significant difference in brain parenchymal fraction loss favoring those patient receiving antibiotics compared with PBO (p< or =0.02). Three of the four patients on antibiotic therapy cleared the organism from the CSF by month 12; in the PBO group one patient cleared the organism. The reduction in atrophy in patients receiving antibiotics must be viewed with caution, due to the small number of patients studied.

Antibiotic treatment of arthritus

Promise of Tetracycline Antibiotic for Osteoarthritis 14 Jul 2005     Study Shows Effectiveness of Doxycycline in Slowing Disease Progression. A tetracycline antibiotic, doxycycline, has been successfully used to treat a wide-range of bacterial infections. In addition to its effects as an antibiotic, doxycycline has other actions as a drug and, in laboratory studies with animals and with human tissue, can inhibit the degradation of cartilage in a way that could be useful for the treatment of osteoarthritis (OA). OA is a common form of arthritis associated with pain and disability related to the breakdown of cartilage, the tissue in the joint that absorbs shock and promotes smooth movement. On the strength of preclinical evidence, a team of rheumatologists affiliated with six clinical research centers across the United States conducted the first long-term clinical trial to determine the benefits of doxycycline in the treatment of OA-particularly, OA of the knee. Their findings, featured in the July 2005 issue of Arthritis & Rheumatismi (, suggest that doxycycline may slow the progression of joint damage and point to the need for further research into the drug's effect on the signs and symptoms of this disease.

Dead Bugs Don't Mutate

Classic and important article on antibiotic resistance by Cpn researcher Charles Strattoni Dead Bugs Don't Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance Charles W. Stratton<

Comments by David Wheldon in response to questions about choice of antibiotics in his protocal versus the Vanderbilt protocal:

I believe that Stratton and co-workers used a beta-lactam (penicillin, amoxycillin or similar) to attack the infectious stage
(elementary body) of the organism. They did some in vitro work to support this, which they should publish, because it's
fundamental. I reasoned that, as culture was so rare in persistent human infections, the numbers of elementary bodies would
be small. Also, any elementary body entering a phagosome in a cell containing bacterial protein-synthesis inhibitors would be
doomed, as the organism needs to fabricate proteins immediately to survive. Coupled with this was a native gut-reaction that
people would buy into the idea more readily if there were fewer antibiotics. And, further, that one is taught at med school
never to combine cidal and static agents. In the higher levels of microbiology that's not always true, but basically you just
want people to believe you and treat, as early as possible, and the more complications you put in their way the more difficult
that is.

Rolling back secondary progressive MS using anti-chlamydials

This link is to Sarah Wheldon's quite eloquent story< of treating for Cpni and her recovery from MS via the protocal developed by her husband, David Wheldoni MD.

This segment written August 2005 for ThisIsMS

Syndicate content